Austin, Texas--(Newsfile Corp. - October 24, 2024) - Maxwell Biosciences is developing a new type of anti-infective drug designed to improve upon natural immune system peptides. The company announced today it has been selected to receive a nearly $3M award from the Medical Technology Enterprise Consortium (MTEC). MTEC works in cooperation with the U.S. Army Medical Research and Development Command (USAMRDC) and the U.S. Department of Defense.

Maxwell Biosciences, a preclinical drug platform company developing a synthetic immune system that may serve as a key biodefense asset, today announced the appointment of Major General (Retired) Barb Holcomb, RN, BSN, MSN to its Board of Directors. This appointment adds one of the world's top national security and biodefense research and logistics executives to Maxwell's board.

Maxwell Biosciences, a pioneering preclinical drug platform company, today announced publication of a revolutionary mechanism of action study for their Claromer® compounds in the journal ACS Infectious Diseases. In this study, the researchers showed how a group of novel molecules - inspired by the human immune system - inactivates several viruses, including all tested Influenza, Coronavirus, Hepatitis, Herpes, Zika and Chikungunya strains. Their approach may lead to drugs that can be used against many viruses, and help overcome wide-ranging challenges with antimicrobial drug resistance.

The Angel Capital Association (ACA) will host "ACA 2023 - The Summit of Angel Investing" (ACA Summit) from May 16-18 in Las Vegas. During the ACA's Innovation Funders Showcase, Maxwell Biosciences (Maxwell), a preclinical drug discovery platform company, will present on their development of synthetic compounds that mimic and enhance molecules found in the innate human immune system designed to treat a broad spectrum of currently untreatable infectious diseases.

Maxwell Biosciences ("Maxwell"), a preclinical drug discovery platform company focused on the development of synthetic compounds that mimic existing human biomolecules (biomimetic therapeutics) from our innate immune system, today announced the appointment of Maxie McFarland, MBA, as Senior Vice President of Corporate Development and Investor Relations. Maxie brings more than 20 years of diverse experience in corporate development and strategy.

Maxwell Biosciences (“Maxwell"), a preclinical drug platform company focused on the development of first-in-class, synthetic small molecules that mimic natural peptides, today announced the appointment of Kate McKinley and Douglas S. Boothe to its Board of Directors. The appointments add experienced pharmaceutical industry CEOs with extensive commercialization, distribution and successful market access expertise to Maxwell’s board. 

Austin, TX – September 29, 2022 – Maxwell Biosciences (“Maxwell”), a preclinical drug platform company focused on the development of synthetic compounds that mimic biomolecules known as biomimetic therapeutics, today announced data on its CLAROMER™ drug discovery platform’s treatment and prevention of SARS-CoV-2, and potentially other respiratory viruses, through a series of pre-clinical in vitro and in vivo studies. The CLAROMER drug discovery platform generates a family of novel compounds to precisely target infectious pathogens. CLAROMERS can exhibit improved stability and potency relative to natural peptides and are highly scalable to manufacture.

Austin, TX – September 22, 2022 – Maxwell Biosciences (“Maxwell"), a preclinical drug platform company focused on the development of synthetic therapeutic compounds that mimic biomolecules, today announced that the Company will present new data on its CLAROMER™ platform’s ability to treat and prevent SARS-CoV-2 and other respiratory viruses at the Options for Control of Influenza (OPTIONS XI) conference, which is hosted by the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) in Belfast, United Kingdom from September 26-29, 2022.

Austin, TX – September 20, 2022 – Maxwell Biosciences (“Maxwell"), a preclinical drug platform company focused on the development of synthetic compounds that mimic biomolecules known as biomimetic therapeutics, today announced the appointments of three senior executives: Tony Verco, MD, MBA, as Chief Medical Officer; Beth Burnside, PhD, as Senior Vice President of Research and Development (R&D) Strategy; and Donald Treacy, Jr., PhD, as Senior Vice President, Development Operations. The appointments further strengthen Maxwell’s management team, bringing industry-leading leadership to support the company’s clinical R&D strategy and operations.

Austin, TX – April 22, 2022 – Maxwell Biosciences today announced the appointment of Edward Rudnic, Ph.D., as Chief Operating Officer, effective immediately. Dr. Rudnic brings more than 30 years of diverse experience in the biosciences industry.

Austin, TX – March 10, 2022 – Maxwell has developed a groundbreaking drug platform technology with the potential to profoundly impact global health. This funding will accelerate our efforts to develop a new class of drugs designed to fight viruses and other pathogens.